Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Rhea-AI Summary

Arcutis Biotherapeutics (Nasdaq: ARQT) reported inducement equity grants to six newly hired employees totaling 51,000 restricted stock units (RSUs) under the company's 2022 Inducement Plan.

The awards were approved by the Compensation Committee with a grant date of November 3, 2025 and were disclosed on November 7, 2025 in accordance with Nasdaq Listing Rule 5635(c)(4). The RSUs vest over four years with 25% vesting on each annual anniversary, subject to continued employment on each vesting date.

WESTLAKE VILLAGE, Calif., Nov. 07, 2025 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a commercial-stage biopharmaceutical company focused on developing meaningful innovations in immuno-dermatology, today reported the grant of an aggregate of 51,000 restricted stock units of Arcutis’ common stock to six newly hired employees. These awards were approved by the Compensation Committee of Arcutis’ Board of Directors and granted under the Arcutis Biotherapeutics, Inc. 2022 Inducement Plan, with a grant date of November 3, 2025, as an inducement material to the new employees entering into employment with Arcutis, in accordance with Nasdaq Listing Rule 5635(c)(4).

The restricted stock units vest over four years, with 25 percent vesting on each annual anniversary of the vesting commencement date, subject to the employee being continuously employed by Arcutis as of such vesting dates.

Arcutis is providing this information in accordance with Nasdaq Listing Rule 5635(c)(4).

About Arcutis

Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT) is a commercial-stage medical dermatology company that champions meaningful innovation to address the urgent needs of individuals living with immune-mediated dermatological diseases and conditions. With a commitment to solving the most persistent patient challenges in dermatology, Arcutis has a growing portfolio of advanced targeted topicals approved to treat three major inflammatory skin diseases. Arcutis’ unique dermatology development platform coupled with our dermatology expertise allows us to develop differentiated therapies against biologically validated targets, and has produced a robust pipeline for a range of inflammatory dermatological conditions. For more information, visit www.arcutis.com or follow Arcutis on LinkedIn, Facebook, Instagram and X.

Forward-Looking Statements
This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. For example, statements contained in this press release regarding matters that are not historical facts are forward-looking statements. These statements are based on the Company’s current beliefs and expectations and are subject to substantial known and unknown risks, uncertainties and other factors that may cause our actual results, levels of activity, performance, or achievements to be materially different from the information expressed or implied by these forward-looking statements. Risks and uncertainties that may cause our actual results to differ include risks inherent in our business, reimbursement and access to our products, the impact of competition and other important factors discussed in the “Risk Factors” section of our Form 10-K filed with the U.S. Securities and Exchange Commission (SEC) on February 25, 2025, as well as any subsequent filings with the SEC. Any forward-looking statements that the company makes in this press release are made pursuant to the Private Securities Litigation Reform Act of 1995, as amended, and speak only as of the date of this press release. Except as required by law, we undertake no obligation to revise or update information herein to reflect events or circumstances in the future, even if new information becomes available.

Contacts:
Media
Amanda Sheldon, Head of Corporate Communications
media@arcutis.com

Investors
Brian Schoelkopf, Head of Investor Relations
ir@arcutis.com

FAQ

What inducement grants did Arcutis (ARQT) disclose on November 7, 2025?

Arcutis disclosed an aggregate grant of 51,000 RSUs to six newly hired employees under its 2022 Inducement Plan, granted on November 3, 2025.

How do the Arcutis (ARQT) RSUs vest for the November 3, 2025 grants?

The RSUs vest over four years with 25% vesting each year on the annual vesting anniversaries, subject to continued employment.

Why did Arcutis (ARQT) issue inducement awards under Nasdaq Listing Rule 5635(c)(4)?

The awards were issued as inducements material to new employees and disclosed to comply with Nasdaq Listing Rule 5635(c)(4) for such hires.

How many employees received inducement RSUs in Arcutis' (ARQT) November 2025 disclosure?

Six newly hired employees received the aggregate 51,000 RSU grant.

Who approved the Arcutis (ARQT) inducement awards granted November 3, 2025?

The awards were approved by the Compensation Committee of Arcutis' Board of Directors.